ArticleJCO oncology practice2021
Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers.
Article in JCO oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Findings and recommendations from a root cause analysis of a clinical trial randomization error.Journal of clinical and translational science · 2026Article
- Article
- Scoping review of oncology clinical trials nursing: Roles, competencies, and evolving practice in cancer research.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2026Article
- Evaluating the impact of delayed study startup on accrual in cancer studies.Contemporary clinical trials communications · 2025Article
- Design and refinement of a clinical trial staffing model within the evolving landscape of oncology clinical trials.Contemporary clinical trials communications · 2025Article
- A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy.Journal for immunotherapy of cancer · 2025Article
- North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era.JCO oncology practice · 2024Article
- The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data.Therapeutic innovation & regulatory science · 2024Review
- Navigating the challenges of clinical trial professionals in the healthcare sector.Frontiers in medicine · 2024Review
- Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.Journal of clinical medicine · 2023Article
- Incivility Is Associated with Burnout and Reduced Compassion Satisfaction: A Mixed-Method Study to Identify Causes of Burnout among Oncology Clinical Research Coordinators.International journal of environmental research and public health · 2021Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
Abstract
purposeCancer clinical trials offices (CTOs) support the investigation of cancer prevention, early detection, and treatment at cancer centers across North America. CTOs are a centralized resource for clinical trial conduct and typically use research staff with expertise in four functional areas of clinical research: finance, regulatory, clinical, and data operations. To our knowledge, there are no publicly available benchmark data sets that characterize the size, cost, volume, and efficiency of these offices, nor whether the metrics differ by National Cancer Institute (NCI) designation. The Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) steering committee developed a survey to address this knowledge gap.
methodsAn 11-question survey that addressed CTO budget, accrual and trial volume, full-time equivalents (FTEs), staff turnover, and activation timelines was developed by the AACI CRI steering committee and sent to 92 academic cancer research centers in North America (n = 90 in the United States; n = 2 in Canada), with 79 respondents completing the survey (86% completion rate).
resultsThe number of FTE employees working in the CTOs ranged from 4.5 to 811 (median, 104). The median number of analytic cases (ie, newly diagnosed or received first course of treatment) reported by the main center was 3,856. Annual CTO budgets ranged from $250,000 to $23,900,000 (median, $8.2 million). The median trial activation time, based on 61 centers, was 167 days. The median number of accruals per center was 480 (range, 5-6,271) and median number of trials per center was 282 (range, 31-1,833). Budget and FTE ranges varied by NCI designation.
conclusionThe response rate to the survey was high. These data will allow cancer centers to evaluate their CTO infrastructure, funding, portfolio, and/or accrual goals as compared with peers. A wide range in each of the outcomes was noted, in keeping with the wide variation in size and scope of cancer center CTOs across the United States and Canada. These variations may warrant additional investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.